Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
AMES, Iowa, April 30, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor conferences:
- Deutsche Bank 43rd Annual Health Care Conference on May 9 at 11:20 AM ET in Boston
- Bank of America Merrill Lynch Global Healthcare Conference 2018 on May 16 at 5:15 PM PT (8:15PM ET) in Las Vegas
A live webcast of both conference presentations will be available on the Company’s website at www.newlinkgenetics.com in the “Investors & Media” section under “Events and Presentations.”
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
[email protected]
Media Contact:
Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
[email protected]
